4月24日,东瑞制药发布年报,2024年实现营业收入10.6亿元,同比下降7.9%;实现归母净利润5.65亿元,同比大幅增长73.3%;基本每股收益为0.38元/股。财报披露,2024年东瑞制药收入下降主要为高血压药品集采降价及苏州、兰州新厂区投产初期产能爬坡影响,净利润增长益于非经常性收益,出售康融东方股权收益2.87亿元及政府搬迁补贴1.05亿元;毛利率为54.48%,同比下降2.25%;加权...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.